Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

40.54EUR
1:15pm GMT
Change (% chg)

€0.66 (+1.65%)
Prev Close
€39.88
Open
€40.28
Day's High
€41.05
Day's Low
€39.98
Volume
1,183,904
Avg. Vol
1,892,032
52-wk High
€71.36
52-wk Low
€38.28

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

  FREG.DE Industry Sector
P/E (TTM): 22.53 27.64 33.63
EPS (TTM): 3.12 -- --
ROI: 9.33 6.83 15.02
ROE: 14.09 10.77 16.60

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

07 Dec 2018

Deals of the day-Mergers and acquisitions

Dec 7 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

07 Dec 2018

UPDATE 2-Fresenius plunges as health firm warns investment to hit profit

* Shares plunge 18 percent, poised for biggest one-day drop (Adds analyst comment, loss in market value)

07 Dec 2018

Fresenius cuts guidance, vows further dividend hikes

FRANKFURT, Dec 7 German healthcare group Fresenius cut its medium-term guidance late on Thursday hurt by lower profit expectations at its dialysis arm FMC and its clinics chain Helios but said that dividends will continue to grow.

07 Dec 2018

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

31 Oct 2018

Fresenius says working to fix performance at dialysis business, German hospitals

BERLIN Germany's Fresenius said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

30 Oct 2018

Fresenius says working to fix performance at dialysis business, German hospitals

BERLIN, Oct 30 Germany's Fresenius said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

30 Oct 2018

German stocks - Factors to watch on Oct. 19

BERLIN, Oct 19 The following are some of the factors that may move German stocks on Friday:

19 Oct 2018

UPDATE 1-Fresenius Medical cuts 2018 targets, sending shares tumbling

* FMC shares slump 13.7 pct, Fresenius down 8.9 pct (Recasts, adds outlook, analyst, trader comment, changes dateline)

17 Oct 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

Earnings vs. Estimates